v3.26.3
Related Parties Transactions - Schedule of Related Parties Transactions (Details) - USD ($)
9 Months Ended
Sep. 30, 2026
Dec. 31, 2025
Sep. 30, 2025
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current     $ 1,934,197
Due to related parties     1,236,996
Previously Reported [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current     2,694,743
Due to related parties     1,201,592
Revision of Prior Period, Adjustment [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current     (760,546)
Due to related parties     35,404
BioFirst [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current [1] $ 934,111 $ 1,521,017  
BioFirst [Member] | Previously Reported [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current   761,017  
BioFirst [Member] | Revision of Prior Period, Adjustment [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current   760,000  
Rgene [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current [2] 2,347 [1]  
Rgene [Member] | Previously Reported [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current   2,347  
Rgene [Member] | Revision of Prior Period, Adjustment [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current    
Director [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current [3] 24 [1]  
Director [Member] | Previously Reported [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current   24  
Director [Member] | Revision of Prior Period, Adjustment [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current    
Related Party [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current 934,111 1,523,388 [4]  
Due from related parties- Non-current, net 963,740 960,193  
Less: allowance for expected credit losses accounts (963,740) (960,193)  
Net  
Due to related parties 1,478,178 865,704 [4]  
Related Party [Member] | Previously Reported [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current   763,388  
Due to related parties   105,704  
Related Party [Member] | Revision of Prior Period, Adjustment [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related party- Current   760,000  
Due to related parties   760,000  
BioFirst (Australia) [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related parties- Non-current, net [5] 839,983 839,983  
BioHopeKing Corporation [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due from related parties- Non-current, net [6] 123,757 120,210  
The Jiangs [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due to related parties [7] 631,531 300 [8]  
The Jiangs [Member] | Previously Reported [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due to related parties   300  
The Jiangs [Member] | Revision of Prior Period, Adjustment [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due to related parties    
Shareholders and Subsidiaries' management [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due to related parties [9] 57,759 [8]  
ForSeeCon [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due to related parties 200,000 [8] 270,000 [8] 200,000
ForSeeCon [Member] | Previously Reported [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due to related parties   70,000  
ForSeeCon [Member] | Revision of Prior Period, Adjustment [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due to related parties   200,000  
OncoX [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due to related parties 560,000 [8] 595,404 [8] $ 560,000
OncoX [Member] | Previously Reported [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due to related parties   35,404  
OncoX [Member] | Revision of Prior Period, Adjustment [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due to related parties   560,000  
Lion Art [Member]      
Schedule of Related Parties Transactions [Line Items]      
Due to related parties $ 28,888 [8]  
BioFirst Corporation (the "BioFirst") [Member]      
Schedule of Related Parties Transactions [Line Items]      
Relationship with the Company and its subsidiaries Entity controlled by controlling beneficiary shareholder of YuanGene    
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”) [Member]      
Schedule of Related Parties Transactions [Line Items]      
Relationship with the Company and its subsidiaries 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene    
Rgene Corporation (the “Rgene”) [Member]      
Schedule of Related Parties Transactions [Line Items]      
Relationship with the Company and its subsidiaries Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang    
GenePharm Inc. (the “GenePharm”) [Member]      
Schedule of Related Parties Transactions [Line Items]      
Relationship with the Company and its subsidiaries Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.    
The Jiangs [Member]      
Schedule of Related Parties Transactions [Line Items]      
Relationship with the Company and its subsidiaries Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirstMs. Shuling Jiang, is the Chairman of Keypoint; and a member of board of directors of the Company and BioLite Inc, and a member of board of directors of BioFirst; a director and beneficial owner of more than 10% of the ABVC’s outstanding common stockMr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is a member of board of directors of BioFirst.Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company, and a member of board of directors of BioFirst.Ms. Mei-Ling Jiang is Ms. Shuling Jiang’s sibling.    
BioLite Japan [Member]      
Schedule of Related Parties Transactions [Line Items]      
Relationship with the Company and its subsidiaries Entity controlled by controlling beneficiary shareholder of ABVC    
BioHopeKing Corporation (“BHK”) [Member]      
Schedule of Related Parties Transactions [Line Items]      
Relationship with the Company and its subsidiaries Entity controlled by controlling beneficiary shareholder of ABVC    
AiBtl (Holding) BioPharma, Inc. (“AiBtl Holding”) [Member]      
Schedule of Related Parties Transactions [Line Items]      
Relationship with the Company and its subsidiaries Founding shareholder of AiBtl BioPharma Inc.    
Jaimes Vargas Russman [Member]      
Schedule of Related Parties Transactions [Line Items]      
Relationship with the Company and its subsidiaries CEO of AiBtl BioPharma Inc.    
Lion Arts Promotion, Inc. (“Lion Arts”) [Member]      
Schedule of Related Parties Transactions [Line Items]      
Relationship with the Company and its subsidiaries Entity controlled by the Jiangs.    
[1] On December 31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of $0.3 million, which bears interest at 12% per annum for the use of working capital. During the year ended December 31, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of $0.4 million, which bears interest at 12% per annum for the use of working capital. In 2025, the Company entered several loan agreements with BioFirst, in the aggregate of $2.1 million. These loans bear 12% per annum, with the term of 12 months. During year ended December 31, 2024 and 2025, the Company received approximately $0.2 million and $1.4 million from BioFirst as repayment of the various loans. In combination with accrued interest of $0.2 million the BioFirst balance resulted in a receivable of $1.5 million (the “BioFirst Balance”) as of December 31, 2025. The funds were used to support BioFirst’ daily operations.
[2] As of September 30, 2026 and December 31, 2025, the Company has other receivables amounted $0 and $2,347, respectively, from Rgene due to daily operations.
[3] The director paid certain operating expenses on behalf of the Company.
[4] Refer to Error Correction in Note 3.
[5] On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On July 27, 2021, the Company repaid a loan 249,975 to BioFirst (Australia). On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $507,000 to increase the cost for upcoming projects.  During the first quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $88,091 to increase the cost for upcoming projects. During the second quarter of 2023, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $25,500 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. For accounting purpose, the due from and due to related party balances was being net off. As of September 30, 2026 and December 31, 2025, the outstanding loan balances and allocated research fee were both amounted to $681,185, and accrued interest balances were both amounted $158,798.
[6] On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the “BHK”) entered into a co-development agreement, (the “BHK Co-Development Agreement”, see Note 4). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of  September 30, 2026 and December 31, 2025, due from BHK was both NTD 3,941,299 (approximately$123,757 and $120,210, respectively). The business conditions of BHK deteriorated and as a result, the Company recognized expected credit losses of NTD 3,941,299 as of December 31, 2024. No recovery was made during the nine months ended September 30, 2026.
[7] Since 2019, the Jiangs advanced funds to the Company for working capital purposes. During year ended 2025, the Company purchased a piece of land in Taiwan from Shuling Jiang, as discussed in Note 5. During the nine months ended September 30, 2026, the Jiang’s advanced funds to the Company for working capital purposes. $0.3 million of the advances bear a monthly interest rate 1% and $0.3 million with 4.5% annum for a term of one year.
[8] As of December 31, 2025, the funds received from ForSeeCon ($200,000) and OncoX ($595,950, of which $546 was paid for then-existing receivables) were initially designated for their payments of licensing fees. In the financial statements as of December 31, 2025, the Company offset payables to ForSeeCon ($200,000) and OncoX ($560,000) with receivables from BioFirst in the amount of $760,000. Upon further review, management determined that these funds did not meet the fund-raising covenant requirements under licensing agreement, recognizing them instead as payables to ForSeeCon and OncoX.

In August 2026, the Company identified this as an accounting error as it did not meet the two-party rule or establish an enforceable right for setoff under ASC 210-20-45. They should have been presented on gross basis. The correction increases Due from related parties and Due to related parties equally by $760,000 at each period end, with corresponding increases in current assets, total assets, current liabilities, and total liabilities. The correction has no effect on revenue, net loss, EPS, equity, cash flows, or working capital. In consideration of ASC 250, SAB 99 and SAB 108, management concluded that the error was not material to the previously issued financial statements, individually or in the aggregate. The Company revised the prior-period information presented herein. The table below shows the effect on payables to related-party and as reported, adjustment, and revised as of December 31, 2025.
[9] In June and September 2026, management of Biokey advanced $38,000 and $19,000, respectively, to Biokey for working capital purposes. The advances bear an interest rate of 3.75% and 4.5% per annum for 6 months and 3 months, respectively.